Growing EU and UK Regulatory Interest in Alleged Excessive Pricing
Introduction Spending on pharmaceuticals constitutes a significant share of public spending on healthcare and is driving increased regulatory scrutiny. Competition authorities in the European Union (EU) and the United Kingdom (UK) have historically been …